Late 2013 start-up Aeglea Biotherapeutics Inc. attracted investments from big pharma venture arms Lilly Ventures and Novartis Venture Fund, which co-led the firm's $44 million series B round to support initial clinical work testing its amino acid-degrading approach in both a rare disease indication and cancer.